Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report
Ohara Mayuko,Takazumi Tsunenari,Takahiro Einama,Koki Ichio,Fukumi Konno,Kazuki Kobayashi,Naoto Yonamine,Yasuhiro Takihata,Mikiya Takao,Akiko Nakazawa,Yoshiki Kajiwara,Hideki Ueno,Yoji Kishi
DOI: https://doi.org/10.3892/ol.2024.14503
2024-06-13
Oncology Letters
Abstract:Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis, and it has a recurrence rate of >70%, even in resectable cases. The treatment strategy for recurrent PDAC involves systemic chemotherapy, with gemcitabine (GEM) monotherapy historically serving as the standard of care. The present study describes the case of a patient with PDAC and postoperative liver metastases that maintained clinical complete remission (cCR) for >7 years following GEM monotherapy. A 63‐year‐old woman with upper abdominal pain was diagnosed with resectable PDAC and underwent pancreaticoduodenectomy. The patient was treated with GEM + S‐1 as adjuvant chemotherapy for 6 months. Multiple liver metastases were detected 15 months post‐operation and the patient was administered GEM alone. After 12 cycles, computed tomography showed cCR and GEM monotherapy was discontinued after 15 cycles. The patient has had no signs or symptoms of recurrence >7 years after the first recurrence. In addition, the present study analyzed PDAC resection specimens from four patients, including this case, to determine the expression levels of hENT1 protein in the tumor tissues. hENT1 is a transmembrane protein that acts as a nucleoside transporter and is a major mediator of GEM uptake into human cells. In the present case, hENT1 staining exhibited low frequency and weak positivity in the central region, whereas a strong positive reaction was observed in nearly all cell membranes at the invasive front of the cancer. The location, intensity, and frequency of hENT1 staining varied among cases. In conclusion, the efficacy of GEM may be predicted prior to treatment by evaluating hENT1 expression.
oncology